文献速递肝病

在初级保健和糖尿病诊疗中评估非酒精性脂肪性肝病高危患者的临床评估

Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices.
PubMed 文献 · Aliment Pharmacol Ther · 2020-06-29

美国全球非酒精性脂肪性肝炎理事会成员评估非酒精性脂肪性肝炎(NASH)及无创检测证据,制定简易算法供初级保健医师和糖尿病医师识别高危NASH患者并转诊至专科。共识推荐以FIB-4作为初始无创检测进行风险分层,FIB-4评分≥1.3可用于进一步评估并链接至专科诊疗。

要点

  • NASH相关进展性肝纤维化是不良结局的独立预测因素,此类患者视为高危,需转诊专科。
  • 共识推荐基于代谢危险因素进行风险分层,以FIB-4作为初始无创检测。
  • FIB-4评分≥1.3可用于进一步评估,并链接至可进行肝脏硬度或血清纤维化检测的专科诊疗。

核心结论

  • 为帮助识别需要专科诊疗的高危NASH患者,提供简易算法供初级保健医师和糖尿病医师使用。

研究设计与样本

  • 美国全球非酒精性脂肪性肝炎理事会成员评估NASH及无创检测证据,制定供糖尿病医师和初级保健提供者识别高危NASH患者的简易算法。

主要发现

  • NASH相关进展性肝纤维化是不良结局的独立预测因素,此类NASH患者视为高危,需转诊专科。
  • 纤维化分期需肝活检,故首选无创纤维化检测。

关键数值与推荐

  • 共识推荐基于代谢危险因素进行风险分层,以FIB-4作为初始无创检测。
  • FIB-4评分≥1.3可用于进一步评估,并链接至可进行肝脏硬度或血清纤维化检测的专科诊疗。

临床怎么用

  • 上述工具可协助一线提供者决策并转诊至胃肠病/肝病专科进行额外评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary care practitioners (PCPs) and diabetologists are at the frontline of potentially encountering patients with NASH. Identification of those at high risk for adverse outcomes is important. AIM: To provide practical guidance to providers on how to identify these patients and link them to specialty care. METHODS: US members of the Global Council on NASH evaluated the evidence about NASH and non-invasive tests and developed a simple algorithm to identify high-risk NASH patients for diabetologists and primary care providers. These tools can assist frontline providers in decision-making and referral to gastroenterology/hepatology practices for additional assessments. RESULTS: The presence of NASH-related advanced fibrosis is an independent predictor of adverse outcomes. These patients with NASH are considered high risk and referral to specialists is warranted. Given that staging of fibrosis requires a liver biopsy, non-invasive tests for fibrosis would be preferred. Consensus recommendation from the group is to risk-stratify patients based on metabolic risk factors using the FIB-4 as the initial non-invasive test due to its simplicity and ease of use. A FIB-4 score ≥1.3 can be used for further assessment and linkage to specialty care where additional technology to assess liver stiffness or serum fibrosis test will be available. CONCLUSION: Due to the growing burden of NAFLD and NASH, PCPs and diabetologists are faced with increased patient encounters in their clinical practices necessitating referral decisions. To assist in identifying high-risk NASH patients requiring specialty care, we provide a simple and easy to use algorithm.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Younossi ZM, Corey KE, Alkhouri N, et al. Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices. Aliment Pharmacol Ther. 2020. PMID: 32598051. doi:10.1111/apt.15830

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。